Amylyx Pharmaceuticals, a company dedicated to developing new treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), will install James Frates as chief financial officer (CFO) on Jan. 25, 2021. Frates has currently worked as the CFO of the global biopharma company Alkermes (NSDQ: ALKS) since 1998.
“We are so excited for Jim to join us at this critical juncture for Amylyx,” said Joshua Cohen, co-CEO and co-founder of Cambridge, Mass.-based Amylyx, in a statement. “Jim’s depth and breadth of experience as a biopharmaceutical executive coupled with his financial acumen and personal mission for bringing promising treatments to patients with ALS make him a fantastic addition to our leadership team.”
“Jim brings the unique combination of experience with growing biopharma companies focused on the central nervous system, both as a CFO and a board member, and passion for the people we serve,” said Justin Klee, co-CEO and co-founder of Am…